U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
SAN ANTONIO, Texas, Aug. 24, 2016 -- bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of patient response to cancer therapy.
The U.S. Patent, entitled “5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine (TCPP) and Kit for Use with Detecting Cancer,” relates to the use of the porphyrin-based CyPath® assay for the early detection of dysplastic, pre-cancerous and cancerous cells from tissue samples both in vitro and in situ. CyPath® preferentially binds to cancer cells, giving them a distinctive fluorescence that can be used to detect cancer at an early stage of the disease by an imaging system.
“The newly awarded patent expands our intellectual property estate and provides important protection as we move toward commercialization of our lung cancer assay,” bioAffinity President and CEO Maria Zannes said. “bioAffinity’s current research on the CyPath® diagnostic and our porphyrin-conjugated chemotherapeutic agents for the delivery of drug therapies is reaching beyond product development to provide greater understanding of the fundamental nature of cancer. We are laying the foundation for a game-changing entry into the cancer diagnosis and treatment markets.”
bioAffinity’s patent portfolio includes 42 awarded patents in 21 countries and six patents pending. U.S. Patent 9,417,241 expands on earlier patents for the detection of precancerous, or dysplastic, cells and cancerous cells based on their unique propensity to take up the bioAffinity assay significantly more than healthy cells.
About bioAffinity Technologies
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers. CyPath® Lung, bioAffinity’s initial product, is designed to be the first successful non-invasive, early-stage lung cancer diagnostic on the market.
Contact: Maria Zannes, 505.400.9747
